Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus STAPHCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus STAPHCILLIN.
AMPICILLIN AND SULBACTAM vs STAPHCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
1-2 g IV every 4-6 hours.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic